Connection

Sonali Kochhar to Humans

This is a "connection" page, showing publications Sonali Kochhar has written about Humans.
Connection Strength

0.112
  1. COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER). Vaccine. 2021 04 28; 39(18):2504-2505.
    View in: PubMed
    Score: 0.007
  2. Expecting the unexpected with COVID-19 vaccines. Lancet Infect Dis. 2021 02; 21(2):150-151.
    View in: PubMed
    Score: 0.007
  3. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines. Vaccine. 2020 09 03; 38(39):6184-6189.
    View in: PubMed
    Score: 0.007
  4. Planning for COVID-19 vaccines safety surveillance. Vaccine. 2020 09 11; 38(40):6194-6198.
    View in: PubMed
    Score: 0.007
  5. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. Vaccine. 2020 07 31; 38(35):5734-5739.
    View in: PubMed
    Score: 0.007
  6. Ethics of Conducting Clinical Research in an Outbreak Setting. Annu Rev Virol. 2020 09 29; 7(1):475-494.
    View in: PubMed
    Score: 0.007
  7. Introduction of new vaccines for immunization in pregnancy - Programmatic, regulatory, safety and ethical considerations. Vaccine. 2019 05 31; 37(25):3267-3277.
    View in: PubMed
    Score: 0.007
  8. Immunization in pregnancy safety surveillance in low and middle-income countries- field performance and validation of novel case definitions. Vaccine. 2019 05 16; 37(22):2967-2974.
    View in: PubMed
    Score: 0.007
  9. Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines. Vaccine. 2019 09 10; 37(38):5796-5802.
    View in: PubMed
    Score: 0.006
  10. Safety assessment of immunization in pregnancy. Vaccine. 2017 12 04; 35(48 Pt A):6469-6471.
    View in: PubMed
    Score: 0.006
  11. Immunization in pregnancy clinical research in low- and middle-income countries - Study design, regulatory and safety considerations. Vaccine. 2017 12 04; 35(48 Pt A):6575-6581.
    View in: PubMed
    Score: 0.006
  12. Time for action: towards an intersectional gender approach to COVID-19 vaccine development and deployment that leaves no one behind. BMJ Glob Health. 2021 08; 6(8).
    View in: PubMed
    Score: 0.002
  13. Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccines. BMJ Glob Health. 2021 05; 6(5).
    View in: PubMed
    Score: 0.002
  14. Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group. Nat Med. 2021 04; 27(4):569-570.
    View in: PubMed
    Score: 0.002
  15. Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety. Pharmacoepidemiol Drug Saf. 2021 07; 30(7):843-857.
    View in: PubMed
    Score: 0.002
  16. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. Vaccine. 2020 11 17; 38(49):7702-7707.
    View in: PubMed
    Score: 0.002
  17. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. Vaccine. 2020 11 17; 38(49):7708-7715.
    View in: PubMed
    Score: 0.002
  18. Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. J Infect Dis. 2020 06 29; 222(2):180-182.
    View in: PubMed
    Score: 0.002
  19. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. Vaccine. 2020 07 22; 38(34):5556-5561.
    View in: PubMed
    Score: 0.002
  20. Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. Vaccine. 2021 01 03; 39(1):85-120.
    View in: PubMed
    Score: 0.002
  21. Assessing feasibility of resources at health facilities in Uganda to diagnose pregnancy and neonatal outcomes. Int Health. 2019 03 01; 11(2):128-135.
    View in: PubMed
    Score: 0.002
  22. Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. J Clin Pharmacol. 2018 10; 58 Suppl 10:S123-S139.
    View in: PubMed
    Score: 0.002
  23. Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation. Vaccine. 2017 12 04; 35(48 Pt A):6472-6482.
    View in: PubMed
    Score: 0.001
  24. Failure to thrive: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017 12 04; 35(48 Pt A):6483-6491.
    View in: PubMed
    Score: 0.001
  25. Low birth weight: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 2017 12 04; 35(48 Pt A):6492-6500.
    View in: PubMed
    Score: 0.001
  26. Neonatal encephalopathy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017 12 04; 35(48 Pt A):6501-6505.
    View in: PubMed
    Score: 0.001
  27. Respiratory distress in the neonate: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 2017 12 04; 35(48 Pt A):6506-6517.
    View in: PubMed
    Score: 0.001
  28. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017 12 04; 35(48 Pt A):6518-6528.
    View in: PubMed
    Score: 0.001
  29. Antenatal bleeding: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2017 12 04; 35(48 Pt A):6529-6537.
    View in: PubMed
    Score: 0.001
  30. Dysfunctional labor: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2017 12 04; 35(48 Pt A):6538-6545.
    View in: PubMed
    Score: 0.001
  31. Fetal growth restriction: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2017 12 04; 35(48 Pt A):6546-6554.
    View in: PubMed
    Score: 0.001
  32. Gestational diabetes mellitus: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2017 12 04; 35(48 Pt A):6555-6562.
    View in: PubMed
    Score: 0.001
  33. Spontaneous abortion and ectopic pregnancy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 2017 12 04; 35(48 Pt A):6563-6574.
    View in: PubMed
    Score: 0.001
  34. Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016 12 01; 34(49):6015-6026.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.